000137775 001__ 137775
000137775 005__ 20210129212109.0
000137775 0247_ $$2doi$$a10.1016/j.neuroimage.2013.04.076
000137775 0247_ $$2ISSN$$a1095-9572
000137775 0247_ $$2ISSN$$a1053-8119
000137775 0247_ $$2WOS$$aWOS:000320412200020
000137775 037__ $$aFZJ-2013-04091
000137775 082__ $$a610
000137775 1001_ $$0P:(DE-HGF)0$$aDepboylu, Candan$$b0$$eCorresponding author
000137775 245__ $$aEffect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry
000137775 260__ $$aOrlando, Fla.$$bAcademic Press$$c2013
000137775 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1378714099_32465
000137775 3367_ $$2DataCite$$aOutput Types/Journal article
000137775 3367_ $$00$$2EndNote$$aJournal Article
000137775 3367_ $$2BibTeX$$aARTICLE
000137775 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137775 3367_ $$2DRIVER$$aarticle
000137775 500__ $$3POF3_Assignment on 2016-02-29
000137775 520__ $$aA previous clinical trial studied the effect of long-term treatment with levodopa (LD) or the dopamine agonist pramipexole (PPX) on disease progression in Parkinson disease using SPECT with the dopamine transporter (DAT)-radioligand [(123)I]β-CIT as surrogate marker. [(123)I]β-CIT binding declined to significantly lower levels in patients receiving LD compared to PPX. However, the interpretation of this difference as LD-induced neurotoxicity, PPX-induced neuroprotection/-regeneration, or only drug-induced regulatory changes of DAT-availability remained controversial. To address this question experimentally, we induced a subtotal lesion of the substantia nigra in mice by bilateral injection of the neurotoxin 6-hydroxydopamine. After 4 weeks, mice were treated for 20 weeks orally with LD (100mg/kg/day) or PPX (3mg/kg/day), or water (vehicle) only. The integrity of nigrostriatal projections was assessed by repeated [(123)I]FP-CIT SPECT in vivo and by immunostaining for DAT and the dopamine-synthesizing enzyme tyrosine hydroxylase (TH) after sacrifice. In sham-lesioned mice, we found that both LD and PPX treatment significantly decreased the striatal FP-CIT binding (LD: -21%; PPX: -14%) and TH-immunoreactivity (LD: -42%; PPX: -45%), but increased DAT-immunoreactivity (LD: +42%; PPX: +33%) compared to controls without dopaminergic treatment. In 6-hydroxydopamine-lesioned mice, however, neither LD nor PPX significantly influenced the stably reduced FP-CIT SPECT signal (LD: -66%; PPX: -66%; controls -66%), TH-immunoreactivity (LD: -70%; PPX: -72%; controls: -77%) and DAT-immunoreactivity (LD: -70%; PPX: -75%; controls: -75%) in the striatum or the number of TH-positive cells in the substantia nigra (LD: -88%; PPX: -88%; controls: -86%), compared to lesioned mice without dopaminergic treatment. In conclusion, chronic dopaminergic stimulation with LD or PPX induced similar adaptive presynaptic changes in healthy mice, but no discernible changes in severely lesioned mice. These findings allow to more reliably interpret the results from clinical trials using neuroimaging of DAT as surrogate parameter.  Copyright © 2013 Elsevier Inc. All rights reserved.
000137775 536__ $$0G:(DE-HGF)POF2-333$$a333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)$$cPOF2-333$$fPOF II$$x0
000137775 588__ $$aDataset connected to
000137775 7001_ $$0P:(DE-HGF)0$$aMaurer, Lukas$$b1
000137775 7001_ $$0P:(DE-Juel1)138474$$aMatusch, Andreas$$b2$$ufzj
000137775 7001_ $$0P:(DE-HGF)0$$aHermanns, Guido$$b3
000137775 7001_ $$0P:(DE-HGF)0$$aWindolph, Andrea$$b4
000137775 7001_ $$0P:(DE-HGF)0$$aBéhé, Martin$$b5
000137775 7001_ $$0P:(DE-HGF)0$$aOertel, Wolfgang H.$$b6
000137775 7001_ $$0P:(DE-HGF)0$$aHöglinger, Günter U.$$b7
000137775 773__ $$0PERI:(DE-600)1471418-8$$a10.1016/j.neuroimage.2013.04.076$$gVol. 79, p. 191 - 200$$p191 - 200$$tNeuroImage$$v79$$x1053-8119$$y2013
000137775 8564_ $$uhttps://juser.fz-juelich.de/record/137775/files/FZJ-2013-04091.pdf$$yRestricted
000137775 909CO $$ooai:juser.fz-juelich.de:137775$$pVDB
000137775 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)138474$$aForschungszentrum Jülich GmbH$$b2$$kFZJ
000137775 9141_ $$y2013
000137775 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000137775 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000137775 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000137775 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000137775 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000137775 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000137775 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000137775 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137775 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000137775 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000137775 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000137775 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000137775 9132_ $$0G:(DE-HGF)POF3-579H$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vAddenda$$x0
000137775 9131_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000137775 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000137775 980__ $$ajournal
000137775 980__ $$aVDB
000137775 980__ $$aUNRESTRICTED
000137775 980__ $$aI:(DE-Juel1)INM-2-20090406